Abrdn PLC Summit Therapeutics Inc. Transaction History
Abrdn PLC
- $51.7 Billion
- Q4 2024
A detailed history of Abrdn PLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Abrdn PLC holds 1,290,425 shares of SMMT stock, worth $28.3 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,290,425
Previous 1,136,286
13.57%
Holding current value
$28.3 Million
Previous $24.9 Million
7.43%
% of portfolio
0.04%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
201Shares Held
76.4MCall Options Held
2.01MPut Options Held
2.83M-
Baker Bros. Advisors LP New York, NY24.4MShares$536 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$240 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$173 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$119 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$76.1 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.42B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...